Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions
Open accessThe DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index; 95 of the 346 sources its claims cite were checked for support.
Abstract
Allometric scaling provides a practical framework for predicting human pharmacokinetic (PK) parameters from animal data by relating physiological processes to body size through power-law equations. Despite its simplicity and widespread use in first-in-human (FIH) dose selection, its predictive performance is limited by species-specific differences in absorption, distribution, metabolism, and excretion (ADME). This review summarizes the mathematical foundations, workflows, and diagnostics of allometric scaling, while critically examining where the approach succeeds and where it fails. Core concepts, including clearance, volume of distribution, correction factors, and the rule of exponents, are discussed alongside complementary methods: in vitro–in vivo extrapolation (IVIVE), physiologically based pharmacokinetic (PBPK) modelling, and the Wajima normalized time-course method. Historical clinical failures, including fialuridine, TGN1412, BIA 10-2474, and rofecoxib, illustrate the limits of relying solely on allometry, while thalidomide and the fenfluramine combination exemplify toxicodynamic species-selection failures. Modern advances, including the Extended Clearance Classification System (ECCS), target-mediated drug disposition, FcRn recycling, and emerging artificial intelligence and machine-learning methods, are integrated within a framework. Overall, the review treats allometric scaling as a disciplined starting hypothesis that must be triangulated with mechanistic, experimental, and regulatory evidence to support safer and more reliable human translation.
Overview
CoChat Summary
TL;DR
Allometric scaling remains a useful but limited starting hypothesis for predicting human pharmacokinetics from animal body weight, because species-specific ADME, transporter, target, and toxicodynamic biology often override size-based relationships. The review integrates classical allometry with correction factors, IVIVE, PBPK, ECCS, TMDD, Wajima normalization, and AI/ML into a mechanism-anchored decision framework for first-in-human dose prediction.
Key findings
- Kleiber’s basal metabolic rate scaling is approximately \(B = aM^{0.75}\), but the review notes the exponent is contested: empirical estimates for physiological and PK parameters typically fall between roughly 0.67 and 0.80, so 0.75 should be treated as a convenient default rather than a biophysical constant.
- In the worked clearance example, OLS regression gave \(\log_{10}(CL) = 0.603 \times \log_{10}(BW) + 0.931\), projecting human CL at 70 kg as approximately 110 mL/min; despite \(R^2 = 0.939\), the 95% confidence interval for the mean prediction spanned roughly 13–905 mL/min and the 95% prediction interval roughly 6–1970 mL/min.
- The rule of exponents recommends simple allometry when the exponent is 0.55–0.70, CL × maximum life-span potential when 0.71–1.0, and a two-term CL × brain-weight equation when the exponent exceeds 1.0; brain-weight correction factors were consistently larger than maximum-life-span factors by approximately 1.3–1.9.
- Lymphatic transport scales differently from systemic clearance: lymph flow and triglyceride mass transport scaled with exponents of approximately 0.84–0.94 and 0.80–0.96, while halofantrine lymphatic mass transport increased with an exponent of approximately 1.3; larger species such as dogs better resemble human lymphatic drug transport than rodents.
Methods
- Narrative, non-systematic review; sources were selected for conceptual and methodological relevance to interspecies PK scaling and first-in-human dose prediction, with emphasis on primary methodological papers, clinical case histories, and regulatory guidance rather than a registered systematic review protocol.
- The review synthesizes classical body-weight allometry, correction factors and the rule of exponents, IVIVE, PBPK, ECCS, target-mediated drug disposition, intestinal lymphatic transport, lysosomal sequestration, and AI/ML approaches into a proposed stepwise decision framework.
- Worked examples in Section 2.2 and Appendix A are hypothetical and constructed for didactic clarity; the Wajima worked example in Section 6.2 uses an independent hypothetical parameter set and is not numerically linked to the clearance example.
Limitations
- The paper states that predictive performance depends critically on the quality and number of preclinical species, with panels of three to four species typical but providing limited leverage; species choice often reflects historical convention rather than mechanistic relevance.
- The paper states that the allometry literature is subject to publication bias toward successful predictions, transporter-mediated scaling carries greater uncertainty than CYP-mediated scaling, idiosyncratic toxicities are not captured by any PK scaling framework, and retrospective benchmarks may not generalize to chemically novel modalities.
- Evident from the text, though not framed as a limitation: the review is non-systematic and does not perform a formal quantitative synthesis or meta-analysis, and its worked examples are hypothetical rather than empirical datasets.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
69 Valid · 20 Not valid · 92 Not checked · 24 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“For monoclonal antibodies (mAbs) and other large biologic therapeutics, simple allometric scaling requires substantial adaptation [26,47].”
§ Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions > 4. Where Size-Based Scaling Breaks > 4.5. Biologics and Target-Mediated Drug Disposition
What the sources say
- Disputedcites [26] Huh Y. Smith D.E. Rose Feng M. Interspecies Scaling and Prediction of Human Clearance: Comparison of Small- and Macro-Molecule Drugs Xenobiotica 2011 41 972 987 10.3109/00498254.2011.598582 21892879 PMC4181675 sourceExperimental — accuracy not yet measured
The Results (Scaling using single species; page unavailable) report that a fixed-exponent allometric equation generally predicted human clearance of macromolecule drugs well, with average-fold error below 2. The Discussion likewise says most predictions were within twofold. This contradicts the claim that simple allometric scaling requires substantial adaptation for these drugs. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [47] Wang W. Wang E. Balthasar J. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics Clin. Pharmacol. Ther. 2008 84 548 558 10.1038/clpt.2008.170 18784655 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“empirical estimates for individual physiological and pharmacokinetic parameters typically falling between roughly 0.67 and 0.80 [7,8].”
§ Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions > 1. Introduction: Rationale for Allometric Scaling
What the sources say
- Partly supportedcites [7] White C.R. Seymour R.S. Mammalian Basal Metabolic Rate Is Proportional to Body Mass2/3 Proc. Natl. Acad. Sci. USA 2003 100 4046 4049 10.1073/pnas.0436428100 12637681 PMC153045 sourceExperimental — accuracy not yet measured
The Results report mammalian basal metabolic rate scaling exponents near 0.67, supporting one physiological example. The paper does not establish that individual physiological parameters typically fall between 0.67 and 0.80, and it does not report pharmacokinetic parameter estimates. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] Dodds P.S. Rothman D.H. Weitz J.S. Re-Examination of the “3/4-Law” of Metabolism J. Theor. Biol. 2001 209 9 27 10.1006/jtbi.2000.2238 11237567 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Third, with only three to four species typically available, the 70 kg prediction intervals are necessarily wider than the point estimates alone would suggest [6,24].”
§ Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions > 3. Mathematics and Diagnostics of the Log–Log Line
What the sources say
- Not checked — no full text of the sourcecites [6] Mahmood I. Misconceptions and Issues Regarding Allometric Scaling during the Drug Development Process Expert Opin. Drug Metab. Toxicol. 2018 14 843 854 10.1080/17425255.2018.1499725 29999428 source
- Partly supportedcites [24] Smoliga J.M. Blanchard O.L. Allometric Scaling Models: History, Use, and Misuse in Translating Resveratrol from Basic Science to Human Clinical Applications FFHD 2017 7 338 10.31989/ffhd.v7i5.345 sourceExperimental — accuracy not yet measured
The Introduction says allometric scaling requires data from at least two species, preferably three. The resveratrol-model section gives a point prediction for a 70 kg human but warns of considerable error because the model uses only two species. The paper does not say that three to four species are typically available or calculate prediction intervals, so it does not support that specific comparison with point estimates. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Kleiber who provided the seminal quantitative synthesis, demonstrating that basal metabolic rate (BMR) scales with body mass to approximately three-quarters of a power law [1,2].”
§ Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions > 1. Introduction: Rationale for Allometric Scaling
What the sources say
- Supportedcites [1] Kleiber M. Body Size and Metabolism Hilgardia 1932 6 315 353 10.3733/hilg.v06n11p315 source
Table 1 (p. 8) reports that basal metabolism across thirteen animal groups fits best when expressed relative to body weight raised to the 0.74 power, approximately three-quarters. The General Conclusions (p. 35) propose a weight-power law, while noting that the best-fitting exponent was not conclusively settled. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [2] Kleiber M. Body Size and Metabolic Rate Physiol. Rev. 1947 27 511 541 10.1152/physrev.1947.27.4.511 20267758 source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“pronounced departures from unity therefore flag compounds whose distribution is governed by lipophilic partitioning or tissue binding rather than by bulk physiological volume [6,26].”
§ Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions > 3. Mathematics and Diagnostics of the Log–Log Line
What the sources say
- Not checked — no full text of the sourcecites [6] Mahmood I. Misconceptions and Issues Regarding Allometric Scaling during the Drug Development Process Expert Opin. Drug Metab. Toxicol. 2018 14 843 854 10.1080/17425255.2018.1499725 29999428 source
- Partly supportedcites [26] Huh Y. Smith D.E. Rose Feng M. Interspecies Scaling and Prediction of Human Clearance: Comparison of Small- and Macro-Molecule Drugs Xenobiotica 2011 41 972 987 10.3109/00498254.2011.598582 21892879 PMC4181675 sourceExperimental — accuracy not yet measured
The Discussion section, “Relationship between CL and molecular size” (page unavailable), says lipophilicity may influence distribution mechanisms. It does not say that departures of a volume-of-distribution exponent from unity flag lipophilic partitioning or tissue binding; its discussion of allometric exponents concerns clearance. (LLM, conf=0.77)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
90 more claims · 31 with their cited sources checked
Create a free account to see all 205 claims and to verify the 8 references still open.
- It may state two separate claims as one. 98
- Probably not a substantial claim. 18
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions > 1. Introduction: Rationale for Allometric Scaling
“The mathematical and physiological foundations of these parameters, articulated in the canonical textbook treatment of Rowland and Tozer [12], underpin all of the operational moves that follow.”
§ Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions > References
“12. Rowland M. Peck C. Tucker G. Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science Annu. Rev. Pharmacol. Toxicol. 2011 51 45 73 10.1146/annurev-pharmtox-010510-100540 20854171”
Citations
Cites
A Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174 · cited 4×
“The most conservative estimate should govern FIH initiation, particularly for novel targets and biologics [15,66–68 Step 7: Variability and uncertainty.”
InfluentialA General Model for the Origin of Allometric Scaling Laws in Biology
West, G. B., Brown, J. H., & Enquist, B. J. (1997) · Science · doi:10.1126/science.276.5309.122 · Cited by 5,016 · cited 2×
“West, Brown, and Enquist [3,4] developed a network-based model to explain the mechanistic origin of Kleiber’s three-quarter power law.”
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 2×
“Substituting the human body weight of 70 kg (log 10 [25] = 1.845) gives log 10 (CL) = 0.603 × 1.845 + 0.931 = 2.043.”
InfluentialCardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519 · cited 1×
“The mechanism is generally ascribed to disruption of the prostacyclin– thromboxane balance, with COX-2-dependent vascular prostacyclin suppressed, without a compensatory effect on platelet COX-1-dependent thromboxane A 2 production [77,78].”
Kleiber, M. (1932) · Hilgardia · doi:10.3733/hilg.v06n11p315 · Cited by 2,222 · cited 2×
“Still, it was Kleiber who provided the seminal quantitative synthesis, demonstrating that basal metabolic rate (BMR) scales with body mass to approximately three-quarters of a power law [1,2].”
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“The failure stemmed from fundamental immunological differences: the distribution of the CD28 receptor on effector memory T cells in humans versus non-human primates produced a qualitatively different pharmacological response [54,71,72].”
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136 · cited 2×
“…the development of ICH S5 reproductive toxicology guidelines mandating evaluation in two species, typically one rodent and one non-rodent, and underlies the broader principle that species panels for toxicodynamic endpoints must be selected on mechanistic grounds rather than convention [55,56].”
De Duve, C., De Barsy, T., Poole, B., Trouet, A., Tulkens, P., & Van Hoof, F. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90174-9 · Cited by 1,901
Lipids and Lipid-Based Formulations: Optimizing the Oral Delivery of Lipophilic Drugs
Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2197 · Cited by 1,824 · cited 6×
“A subset, however, associates with the triglyceride-rich lipoproteins assembled during lipid absorption and is carried instead into the intestinal lymphatics, entering the systemic circulation at the thoracic duct, and so bypassing the liver on first pass [28,29].”
InfluentialKleiber, M. (1947) · Physiological Reviews · doi:10.1152/physrev.1947.27.4.511 · Cited by 1,817 · cited 1×
“Still, it was Kleiber who provided the seminal quantitative synthesis, demonstrating that basal metabolic rate (BMR) scales with body mass to approximately three-quarters of a power law [1,2].”
Research works printed but not linked: 1
- Institute of Medicine (US) Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials Review of the Fialuridine (FIAU) Clinical Trials Manning F.J. Swartz M. Institute of Medicine (US) Washington, DC, USA 1995 25121268
Cited by
Satapathy, T., Satapathy, A., Sahu, P., & Satapathy, A. (2026) · Biomaterials and Living Medicine for Pharmaceutics · doi:10.1016/j.bioliv.2026.100011
Zhang, L., & Xu, Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101256 · Cited by 1
Metadata
- Authors
- Mallillin, M. C., Silva, D. A., Miller, N. A., Zhao, S., Salami, M., Löbenberg, R., & Davies, N. M.
- Affiliations
- University of Alberta (CA)
- Simulations Plus (United States) (US)
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2H7, Canada
- Corresponding author
- Löbenberg, Raimar
- Davies, Neal M.
- ORCID
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2026-07-03
- Volume
- 18
- Issue
- 7
- Pages
- 824
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC13414681
- OpenAlex
- W7167236904
- Cited by
- 2
- References
- 96
- Citations by year
- 2026: 2
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- allometric scaling, first-in-human dose selection, interspecies extrapolation, clearance, volume of distribution, correction factors, in vitro-in vivo extrapolation, physiologically based pharmacokinetic modelling, ADME, target-mediated drug disposition, thalidomide, fenfluramine, rofecoxib, TGN1412, FIAU, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.